220655-09-4

Basic information

• Product Name: TERT-BUTYL THIOMORPHOLINE-4-CARBOXYLATE
• Synonyms: TERT-BUTYL THIOMORPHOLINE-4-CARBOXYLATE;EOS-61422
• CAS NO: 220655-09-4
• Molecular Formula: C₉H₁₇NO₂S
• Molecular Weight: 203.30178
• Mol File: 220655-09-4.mol
• Article Data: 18

Chemical Properties

• Appearance: /
• CAS DataBase Reference: TERT-BUTYL THIOMORPHOLINE-4-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL THIOMORPHOLINE-4-CARBOXYLATE(220655-09-4)
• EPA Substance Registry System: TERT-BUTYL THIOMORPHOLINE-4-CARBOXYLATE(220655-09-4)

Safety Data

• Hazardous Substances Data: 220655-09-4(Hazardous Substances Data)

Usage

Uses

tert-Butyl thiomorpholine-4-carboxylate is used as a reactant in the preparation of aromatic heterocyclic ureas as antiinflammatory agents.

Upstream product

• 123-90-0 Thiomorpholin 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 73286-70-1 N-(tert-butoxycarbonyl)-3-pyrroline 
• 39093-93-1 thiomorpholine 1,1-dioxide 
• 278788-74-2 tert-butyl thiomorpholine-4-carboxylate-1-oxide 
• 215791-95-0 tert-butyl thiomorpholine-4-carboxylic acid-1,1-dioxide 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS

Provided herein are compounds of formula (I) which comprise a thiomorpholine 1,1-dioxide or 1-imino-thiomorpholine 1-oxide moiety, or pharmaceutically acceptable salts of any of the foregoing, pharmaceutical compositions that include a compound described herein (including salts of the compound) and methods of synthesizing the same. Also provided are methods of treating Hepatitis B viral (HBV) infections using a compound of formula (I), or pharmaceutically acceptable salts thereof.

PYRROLIDINE GLYCOSIDASE INHIBITORS

Compounds of formula (I) wherein A, W, R3b, Z and p have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

Neurotrophic factor tyrosine kinase receptor inhibitor

The invention provides a neurotrophic factor tyrosine kinase receptor inhibitor. The tyrosine kinase receptor inhibitor provided by the invention has a tricyclic parent core structure, can inhibit theactivity of Trk kinase and can be used for treating mammalian diseases mediated by the Trk kinase.